| Literature DB >> 29206345 |
Martina Durcik1, Päivi Tammela2, Michaela Barančoková1, Tihomir Tomašič1, Janez Ilaš1, Danijel Kikelj1, Nace Zidar1.
Abstract
ATP-competitive inhibitors of DNA gyrase and topoisomerase IV are among the most interesting classes of antibacterial drugs that are unrepresented in the antibacterial pipeline. We developed 32 new N-phenylpyrrolamides and evaluated them against DNA gyrase and topoisomerase IV from E. coli and Staphylococcus aureus. Antibacterial activities were studied against Gram-positive and Gram-negative bacterial strains. The most potent compound displayed an IC50 of 47 nm against E. coli DNA gyrase, and a minimum inhibitory concentration (MIC) of 12.5 μm against the Gram-positive Enterococcus faecalis. Some compounds displayed good antibacterial activities against an efflux-pump-deficient E. coli strain (MIC=6.25 μm) and against wild-type E. coli in the presence of efflux pump inhibitor PAβN (MIC=3.13 μm). Here we describe new findings regarding the structure-activity relationships of N-phenylpyrrolamide DNA gyrase B inhibitors and investigate the factors that are important for the antibacterial activity of this class of compounds.Entities:
Keywords: DNA gyrase; GyrB; antibacterials; inhibitors; pyrrolamides
Mesh:
Substances:
Year: 2018 PMID: 29206345 DOI: 10.1002/cmdc.201700549
Source DB: PubMed Journal: ChemMedChem ISSN: 1860-7179 Impact factor: 3.466